Waldencast plc - Class A Ordinary Share (WALD) is currently showing a neutral headline tone with a mixed / range backdrop. The latest news flow is being framed here as context rather than prediction, so beginners can quickly see whether headlines are helping, hurting, or complicating the chart story. Earnings tone is currently no clear earnings read.
HEADLINE TAKE: The current headline mix looks balanced, so the overall news tone reads neutral right now.
Change stock
Search another ticker to view its latest news page.
Full chart, indicators and drawing tools on TradingView. Move to Platforms when you are ready to act.
MyStockHarbor
NEWS SCORE
44/100
Neutral
Bearish
Neutral
Bullish
Earnings Tone
55
Neutral based on actual EPS/revenue
Confidence
Medium
Headline depth
Last Price
$1.71
Trend Context
Mixed / range
Latest briefing
What's happening with WALD
globenewswire.com15 Jun 2026
Obagi Medical Announces FDA Approval of Obagi® saypha® ChIQ™ Injectable Hyaluronic Acid Gel
LONDON, June 15, 2026 (GLOBE NEWSWIRE) -- Waldencast plc (NASDAQ: WALD) (“Waldencast” or the “Company”), a global multi-brand beauty and wellness platform, today announced that the U.S. Food and Drug Administration (“FDA”) has approved Obagi® saypha® ChIQ™ injectable hyaluronic acid (“HA”) gel, the latest addition to the Obagi® injectable portfolio under the Obagi Medical brand. This approval builds on the launch of Obagi® saypha® MagIQ™ and accelerates Obagi Medical's strategy to establish Obagi as a comprehensive…
Article excerpt provided by the FMP news feed. AI is used only for the optional "Why this matters" read.Read full article ↗
globenewswire.com1 Jun 2026
Waldencast Announces Sale of Obagi Medical to Bridgepoint
LONDON, June 01, 2026 (GLOBE NEWSWIRE) -- Waldencast plc (NASDAQ: WALD) (“Waldencast” or “the Company”) today announced that it has entered into a definitive agreement to sell its Obagi Medical dermatological skincare and aesthetics business (“Obagi Medical”) to Bridgepoint, one of the world's leading mid-market investors, in a transaction valued at up to $460 million, marking a significant step in Waldencast's strategy to strengthen its balance sheet and focus on accelerating the global growth of Milk Makeup.
Article excerpt provided by the FMP news feed. AI is used only for the optional "Why this matters" read.Read full article ↗
globenewswire.com15 May 2026
Obagi Medical Shares New Data on Recent Innovations at Music City Symposium for Cosmetic Advances & Laser Education (SCALE) Meeting
Data from the ALOHA Program and NU-GEN™ Cellular Renewal Serum Showcase Results to Help Drive Practice Success Data from the ALOHA Program and NU-GEN™ Cellular Renewal Serum Showcase Results to Help Drive Practice Success
Article excerpt provided by the FMP news feed. AI is used only for the optional "Why this matters" read.Read full article ↗
Older updates drop into a lighter feed
globenewswire.com
14 May 2026
Obagi and Next Health Partner to Launch “The Skin Recharge Station” Pop-Up Experience
